Dendritic cell maturation with CpG for tumor immunotherapy

Iranian Journal of Immunology

Volumn 3, Issue 3, 2006, Pages 99-105

  Arab, Samaneh ^a   Motamedi, Masoumeh ^a   Khansari, Nematollah ^a   Moazzeni, Seied Mohammad ^b   Gheflati, Zahra ^a   Hadjati, Jamshid ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Cancer; CpG Oligonucleotide; Dendritic cell; Immunotherapy

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGONUCLEOTIDE 1826; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 4; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL MATURATION; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; FEMALE; MOUSE; NONHUMAN; TUMOR GROWTH;

EID: 33751201803     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Steinman RM. The dendritic cell system and its role in immunogenicity.Annu Rev Immunol. 1991;9:271-96.
2. Freudenthal PS, Steinman RM. The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc Natl Acad Sci U S A. 1990;87:7698-702.
3. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B et al. Proliferating dendritic cell progenitors in human blood.J Exp Med. 1994;180:83-93.
4. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.J Exp Med. 1994;179:1109-18.
5. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.J Exp Med. 1995;182:389-400.
6. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses.Immunity. 2003;19:641-4.
7. Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 2001;22:269-76.
8. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma.Blood. 1997;89:2994-8.
9. Davila E, Celis E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol. 2000;165:539-47.
10. Blazar BR, Krieg AM, Taylor PA Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood. 2001;98:1217-25.
11. Sharma S, Karakousis CP, Takita H, Shin K, Brooks SP. Intra-tumoral injection of CpG results in the inhibition of tumor growth in murine Colon-26 and B-16 tumors.Biotechnol Lett. 2003;25:149-53.
12. Carpentier AF, Xie J, Mokhtari K, Delattre JY. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs.Clin Cancer Res. 2000;6:2469-73.
13. Baines J, Celis E. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin Cancer Res. 2003;9:2693-700.
14. Carpentier AF, Chen L, Maltonti F, Delattre JY. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice.Cancer Res. 1999;59:5429-32.
15. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675-80.
16. Weiner GJ. CpG DNA in cancer immunotherapy.Curr Top Microbiol Immunol. 2000;247:157-70.
17. Walker PS, Scharton-Kersten T, Krieg AM, Love-Homan L, Rowton ED, Udey MC et al . Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gammadependent mechanisms.Proc Natl Acad Sci U S A. 1999;96:6970-5.
18. Gramzinski RA, Doolan DL, Sedegah M, Davis HL, Krieg AM, Hoffman SL. Interleukin-12- and gamma interferondependent protection against malaria conferred by CpG oligodeoxynucleotide in mice.Infect Immun. 2001;69:1643-9.
19. Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M et al. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs.J Immunol. 2001;167:4878-86.
20. Sharma S, Karakousis CP, Takita H, Shin K, Brooks SP. Intra-tumoral injection of CpG results in the inhibition of tumor growth in murine Colon-26 and B-16 tumors.Biotechnol Lett. 2003;25:149-53.
21. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdorfer B et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model.J Immunol. 2002;169:3892-9.
22. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells.Cell. 2001;106:263-6.
23. Kumar S, McDonnell PC, Lehr R, Tierney L, Tzimas MN, Griswold DE et al. Identification and initial characterization of four novel members of the interleukin-1 family.J Biol Chem. 2000;275:10308-14.
24. Knight SC, Hunt R, Dore C, Medawar PB. Influence of dendritic cells on tumor growth.Proc Natl Acad Sci U S A. 1985;82:4495-7.
25. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.Adv Immunol. 1991;49:281-355.